Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.47 |
| ▸ | CA6 | P23280 | 2/20 | 0.47 |
| ▸ | CA5A | P35218 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2434893 | 1.00 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL17821906 | 0.91 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL17821908 | 0.91 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL7138837 | 0.90 | NFE2L2 (0.59) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL8572433 | 0.90 | NFE2L2 (0.59) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL16911736 | 0.82 | PTGS2 (0.46) | ALDH1A1SMN1; SMN2KDM4EHPGDPTGS2 | |
| SCHEMBL5888801 | 0.81 | EIF2AK2 (0.46) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL5888800 | 0.81 | EIF2AK2 (0.46) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL31501087 | 0.81 | EIF2AK2 (0.46) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 | |
| SCHEMBL11687468 | 0.81 | KDM4E (0.43) | ALDH1A1SMN1; SMN2KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8598374-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130109734-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| EP-2582674-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | Metabolex Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2367793-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX INC (US) | 2013-03-27 | — | — | EP | disclosed |
| US-8309600-B2 | GPR120 receptor agonists and uses thereof | METABOLEX INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8299117-B2 | GPR120 receptor agonists and uses thereof | METABOLEX INC. (US) | 2012-10-30 | — | — | US | disclosed |
| WO-2010080537-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-0628311-B1 | Xanthine-Derivatives as Antidepressants | KYOWA HAKKO KOGYO KK (JP) | 2002-04-24 | — | — | EP | disclosed |
| EP-0590919-B1 | Therapeutic agents for parkinson's disease | KYOWA HAKKO KOGYO KK (JP) | 1999-12-29 | — | — | EP | disclosed |
| EP-0565377-B1 | Therapeutic agents for use in the treatment of Parkinson's Disease | KYOWA HAKKO KOGYO KK (JP) | 1998-01-07 | — | — | EP | disclosed |
| US-5587378-A | ADMINISTERING A SUBSTITUTED XANTHINE COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| US-5543415-A | ADMINISTERING A XANTHINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-08-06 | — | — | US | disclosed |
| US-5484920-A | XANTHINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-01-16 | — | — | US | disclosed |
| EP-0628311-A1 | ANTIDEPRESSANT | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-12-14 | — | — | EP | disclosed |
| EP-0590919-A1 | Therapeutic agents for parkinson's disease | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-04-06 | — | — | EP | disclosed |
| EP-0565377-A1 | Therapeutic agents for use in the treatment of parkinson's disease | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | ALDH1A1 3347/4885SMN1; SMN2 3326/4885KDM4E 4479/4885 |
| US-20130109734-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | ALDH1A1 3347/4885SMN1; SMN2 3326/4885KDM4E 4479/4885 |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | ALDH1A1 3347/4885SMN1; SMN2 3326/4885KDM4E 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.